[{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"TFC-1067","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Sirona Biochem","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Sirona Biochem"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"International Centre for Genetic Engineering and Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Antiviral Therapeutics","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"RODAN & FIELDS LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Difluorocyclohexyloxyphenol","moa":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ RODAN & FIELDS LLC","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ RODAN & FIELDS LLC"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sirona Biochem Corp

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : GlycoProteMim (TFC-1326) is Sirona’s lead anti-aging compound, a topical cream small molecule drug candidate, with potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.

                          Brand Name : GlycoProteMim

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 11, 2023

                          Lead Product(s) : TFC-1326

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TFC-1326 is Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.

                          Brand Name : TFC-1326

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 25, 2023

                          Lead Product(s) : TFC-1326

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The ICGEB has successfully screened a library of 20 compounds produced at Sirona’s subsidiary TFChem as potential inhibitors of SARS-CoV-2 using specialized assays developed at the centre.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 27, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients. The trial is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine...

                          Brand Name : TFC-1326

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 08, 2022

                          Lead Product(s) : TFC-1326

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.

                          Brand Name : TFC-039

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : TFC-039

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Wanbang Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies.

                          Brand Name : TFC-1326

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 16, 2022

                          Lead Product(s) : TFC-1326

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Lead Product(s) : Antiviral Therapeutics

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Discovery

                          Sponsor : International Centre for Genetic Engineering and Biotechnology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : Scientists at ICGEB will test the potential antivirals against SARS-CoV-2 (COVID-19) using specialized assays developed at the centre.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 10, 2022

                          Lead Product(s) : Antiviral Therapeutics

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : International Centre for Genetic Engineering and Biotechnology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.

                          Brand Name : TFC-1326

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 22, 2022

                          Lead Product(s) : TFC-1326

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Recipient : WuXi AppTec

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and...

                          Brand Name : TFC-1067

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 13, 2022

                          Lead Product(s) : Difluorocyclohexyloxyphenol

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : Allergan Aesthetics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorpo...

                          Brand Name : TFC-1067

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 16, 2022

                          Lead Product(s) : Difluorocyclohexyloxyphenol

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : RODAN & FIELDS LLC

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank